The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C09 | Agents acting on the renin-angiotensin system | |
3
|
C09X | Other agents acting on the renin-angiotensin system | |
4
|
C09XX | Other agents acting on the renin-angiotensin system | |
5
|
C09XX01 |
| Active Ingredient |
|---|
|
Sparsentan is a dual endothelin angiotensin receptor antagonist. It is a single molecule that functions as a high affinity, dual-acting antagonist of both the ETAR and AT1R. Endothelin 1, via ETAR, and angiotensin II, via AT1R, mediate processes that lead to IgAN progression through haemodynamic actions and mesangial cell proliferation, increased expression and activity of proinflammatory and profibrotic mediators, podocyte injury, and oxidative stress. Sparsentan inhibits activation of both ETAR and AT1R and thereby reduces proteinuria and slows the progression of kidney disease. |
| Document | Type | Information Source | |
|---|---|---|---|
| FILSPARI Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| FILSPARI Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.